New York City dermatologist Perry Robins, MD has joined Emerald Medical Applications Corp.’s advisory board.

Emerald, an Israeli-based company, is developing DermaCompare™, a proprietary artificial intelligence free app for the early diagnosis of melanoma and other skin cancers. The app is US Food and Drug Administration Class #1 approved, HIPPA-compliant.

Dr. Robins is Professor Emeritus of Dermatology and was Chief of the Mohs Micrographic Surgery Unit at New York University Medical Center. He is also the Founder and President of The Skin Cancer Foundation, the Founder-President of the International Society for Dermatologic Surgery, Founder and former President of the American College of Mohs Micrographic Surgery,  Former President of the American Society of Dermatologic Surgery and an honorary fellow at the American Academy of Dermatology.

"I am very excited to join Emerald. I have dedicated a large portion of my long career in dermatology to the treatment of skin cancers, but I have never seen anything like DermaCompare,” Dr Robins says in a news release.  “I believe their ability to combine the power of artificial intelligence with the utility of a mobile app will revolutionize the way we detect and diagnose melanoma, and I look forward to working with the company on this endeavor."

The DermaCompare™ patient app is available in Mac or Android based platforms and works using virtually any digital camera, including cell phones, iPads, tablets and other similar devices, to take Total Body Photography images and, in real-time, transmit these images for dermatological evaluation and identification of suspicious moles, lesions and other skin conditions. These images are then compared using Emerald's cloud database, as well as the patient's previous Total Body Photography images.